Research programme: antifungals - GPC BiotechAlternative Names: Cak1 inhibitors - GPC Biotech; GGTase inhibitors - GPC Biotech
Latest Information Update: 05 May 2003
At a glance
- Originator GPC Biotech Inc
- Class Small molecules
- Mechanism of Action CDC2 protein kinase inhibitors; Geranylgeranyltransferase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Mycoses
Most Recent Events
- 05 May 2003 This antifungal research programme is available for licensing (http://www.gpc-biotech.com)
- 11 May 2000 Preclinical development for Mycoses in USA (Unknown route)